The nurses role in administration of intravenous immunoglobulin therapy

Home Healthcare Nurse

Volumn 27, Issue 2, 2009, Pages 104-111

  Kirmse, Jane ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ASEPTIC MENINGITIS; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMMUNITY HEALTH NURSING; DRUG APPROVAL; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOLOGY; INFUSION; METHODOLOGY; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; PATIENT EDUCATION; PATIENT SELECTION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; UNITED STATES;

ANAPHYLAXIS; CHEMISTRY, PHARMACEUTICAL; COMMUNITY HEALTH NURSING; DRUG APPROVAL; DRUG MONITORING; HOME INFUSION THERAPY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; KIDNEY FAILURE, ACUTE; MENINGITIS, ASEPTIC; NURSE'S ROLE; NURSING ASSESSMENT; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; THROMBOEMBOLISM; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 67449106661     PISSN: 0884741X     EISSN: 15390713     Source Type: Journal    
DOI: 10.1097/01.NHH.0000346313.64380.da     Document Type: Article

References (34)

1. Abrahamsen, T. G., Sandersen, H., & Bustnes, A. (1996). Home therapy with subcutaneous immunoglobulin infusion in children with congenital immunodefi-ciencies. Pediatrics, 98(6), 1127-1131.
2. Ballow, M. (2002). Intravenous immunoglobulins: Clinical experience and viral safety. Journal American Pharmacy Association, 42, 449-458.
3. Bruton, O. C. (1952). Agammaglobulinemia. Pediatrics, 9, 722-727.
4. Chapel, H. M., Spickett, G. P., Ericson, D., Engl, W., Eibl, M. M., & Bjorkander, J. (2000). The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. Journal of Clinical Immunology, 20(2), 94-100.
5. Cowden, J., & Parker, S. K. (2006). Intravenous im-munoglobulin. The Pediatric Infectious Disease Journal, 25(7), 641-642.
6. Dalakas, M. C. (1994). High-dose intravenous im-munoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology, 44, 223-226.
7. Dalakas, M. C. (1999). Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle Nerve, 22(11), 1479-1497.
8. Davé, S., & Hagan, J. (2007). Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration. Annals of Allergy, Asthma & Immunology, 99, 567-570.
9. De Albuquerque, C. R., Sato, M. N., & da Silva, D. A. J. (2000). IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reaction to intravenous immunoglobulin therapy. Journal of Clinical Immunology, 20, 77-82.
10. Duff, K. (2006). You can make a difference in the administration of intravenous immunoglobulin therapy. Journal of Infusion Nursing, 29(3S), S5-S14.
11. Gardulf, A., Andersen, V., Bjorkander, J., Ericson, D., Froland, S.S., Gustafson, R., et al. (1995a). Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet, 345, 365-369.
12. Gardulf, A., Bjorvell, H., Andersen, V., Bjorkander, J., Er-icson, D., Froland, S.S., et al. (1995b). Lifelong treatment with gammaglobulin for primary antibody deficiencies: The patients' experiences of subcutaneous self-infusions and home therapy. Journal of Advanced Nursing, 21, 917-927.
13. Gardulf, A., Hammarstrom, L., & Smith, E. (1991). Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet, 338, 162-166.
14. Gardulf, A., Nicolay, U., Math, D., Asensio, O., Berna-towska, E., Bock, A., et al. (2004). Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. Journal of Allergy and Clinical Immunology, 114, 936-942.
15. Gelfand, E. W. (2005). Critical decisions in selecting an intravenous immunoglobulin product. Journal of Infusion Nursing, 28(6), 366-374.
16. Immune Deficiency Foundation. (2003, June). Treatment experiences and preferences of patients with primary immune deficiency. Retrieved June, 2008 from http://www.primaryimmune.org.html
17. Immune Deficiency Foundation. (2007). IDF guide for nurses on immune globulin therapy for primary im-munodeficiency diseases. In R. M. Blaese (Ed.). Tow-son, MD: Author.
18. Kazatchkine, M. D., & Kaveri, S. V. (2001). Immunomod-ulation of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine, 345, 747-755.
19. Kirmse, J. (2006). Subcutaneous administration of im-munoglobulin. Journal of Infusion Nursing, 29(3S), S15-S20.
20. Murphy, E., Martin, S., & Valino-Patterson, J. (2005). Developing practice guidelines for the administration of intravenous immunoglobulin. Journal of Infusion Nursing, 28(4), 265-272.
21. National Institutes of Health. (1990). Consensus development conference intravenous immune globulin: prevention and treatment of diseases. Consensus Statement. Bethesda MD: Department of Health and Human Services, 8(5)
22. NIAID Expert Panel. (1998, April). Effects of donor pool size. Retrieved June 2008 from http://www.niaid.nih-gov/chart/ivig1.html
23. Nydegger, U., & Sturzenegger, M. (1999). Adverse effects of intravenous immunoglobulin therapy. Drug Safety, 21, 171-185.
24. Ochs, H. (2006). CE1200 Study Group. Results of the US pivotal trial of self administration subcutaneous im-munoglobulin replacement therapy in primary immune deficiency diseases. Abstract presented at the American Academy of Allergy, Asthma, & Immunology Annual Meeting, March 5, 2006, Miami Beach, Florida.
25. Orange, J. S., Hossny, E. M., Weiler, C. R., Ballow, M., Berger, M., Bonilla, F. A., et al. (2006). Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunode-ficiency committee of the American academy of allergy, asthma and immunology. Journal of Allergy Clinical Immunology, 117(4), S525-S553.
26. Phase III clinical study shows Vivaglobin, a new subcutaneous immunoglobulin is safe and effective in treating patients with primary immunodeficiency: Study shows patients associated with improved quality of life. Abstract. Retrieved June 2008 from http://www.vivaglobin.com.
27. Radinsky, S., & Bonagura, V. R. (2003). Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. Journal of Allergy and Clinical Immunology, 112(3), 630-633.
28. Reid, B. K, VanAllen, D., LaGrange, C., & Boissonneault, N. (2006). Protocol recommendations for administration of intravenous immunoglobulin in Canada. Journal of Infusion Nursing, 29(3), 158-164.
29. Sacher, R. A., & the IVIG Advisory Panel. (2001). Intravenous immunoglobulin consensus statement. Journal of Allergy and Clinical Immunology, 108(4), S139-S146.
30. Schleis, T. (2000). The financial, operational, and clinical management of intravenous immunoglobulin administration. Journal of Intravenous Nursing, 23(5S), S23-S31.
31. Shah, S. M. A., & Graeber, C. W. (2005, March). Acute renal failure following intravenous immunoglobulin therapy. Hospital Physician, 41(3), 29-32.
32. Stiehm, E. R. (1997). Human intravenous immunoglobu-lin in primary and secondary antibody deficiency. Pediatric Infectious Disease Journal, 16, 696-707.
33. U.S. Food and Drug Administration. (2007). Immune globulin intravenous (IGIV) indications. Retrieved June 2008 from http://www.fda.gov/cber/products/ igivlist.html.
34. Weiler, C. R. (2004). Immunoglobulin therapy: History, indications, and routes of administration. International Journal of Dermatology, 43, 163-166.